Sunil R. Hingorani
M.D., Yale University, Medicine, 1994.
Ph.D., Yale University, Cellular & Molecular Physiology, 1994.
B.S., Yale University, Molecular Biophysics & Biochemistry, 1985.
PDA is a nearly uniformly lethal disease that defies all forms of conventional chemotherapy and radiotherapy. The same factors that conspire to obscure the diagnosis of the disease in patients until very advanced stages also hinder the study of its pathogenesis. Our laboratory has worked to develop animal models that faithfully mimic the clinical and histopathologic progression of human pancreatic ductal adenocarcinoma (PDA) from its earliest precursor lesions to invasive and metastatic disease. The murine models form the basis for our efforts to elucidate mechanisms of disease pathogenesis, to identify biomarkers associated with each stage of disease and, potentially, with disease response to specific therapies; and to develop and test strategies for chemoprevention and treatment. Our investigations have also helped identify unique genetic routes to PDA with distinct clinical and histopathologic features. Thus, the models should also provide more rigorous platforms for preclinical studies of disease-specific detection and treatment strategies that will be more predictive of efficacy in patients.
American Association for Cancer Research
Honors and Awards
2007, Scientific Director, Michael Rolfe Pancreatic Cancer Foundation
2005, Laurence A. Mack Career Development Award in Pancreatic Cancer Research, American Association for Cancer Research/PanCAN Foundation
2004, Scholar in Training Award, American Association for Cancer Research
1988-1993, Howard Hughes Pre-Doctoral Fellowship Award, Howard Huges Foundation
1985, Summa cum laude, Yale University
1983, Phi Beta Kappa Honor Society, Phi Beta Kappa Honor Society
2006-2011, Assistant Professor, Department of Medicine, University of Washington School of Medicine, Seattle, WA
2005-2010, Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research, Public Health Sciences
2003-2005, Attending Physician, Philadelphia Veterans' Administration Medical Center, Hematology/Oncology
2002-2005, Instructor, University of Pennsylvania, Abramson Cancer Center and Abramson Family Cancer Research Institute, Medicine and Cancer Biology
1999-2000, Post-Doctoral Research Fellow, Massachusetts Institute of Technology
1997-2000, Clinical Fellow, Brigham and Women's Hospital, Internal Medicine
1997-2000, Clinical Fellow, Dana-Farber/Partners Cancer Care Program, Hematology and Oncology
1994-1997, Intern, Brigham and Women's Hospital, Department of Internal Medicine
Stromal re-engineering to treat pancreas cancer.. Carcinogenesis.. 2014.
Molecular Pathways: Myeloid Complicity in Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research.. 2014.
Re-adapting T cells for cancer therapy: from mouse models to clinical trials.. Immunological reviews. 257(1):145-64.. 2014.
Vitamin E δ-Tocotrienol Prolongs Survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) Transgenic Mouse Model of Pancreatic Cancer.. Cancer prevention research (Philadelphia, Pa.). 6(10):1074-83.. 2013.
Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.. Cancer research. 73(11):3235-47.. 2013.
Pancreas cancer meets the thunder god.. Science translational medicine. 4(156):156ps21.. 2012.
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.. Cancer cell. 21(3):418-29.. 2012.
Changes in connexin43 expression and localization during pancreatic cancer progression.. The Journal of membrane biology. 245(5-6):255-62.. 2012.
Isoform-specific upregulation of palladin in human and murine pancreas tumors.. PloS one. 5(4):e10347.. 2010.
Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(33):5660-9.. 2009.
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.. Science (New York, N.Y.). 324(5933):1457-61.. 2009.
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(15):4836-42.. 2008.